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ABSTRACT 
 
To identify new risk loci for colorectal cancer (CRC) we conducted a meta-analysis of seven 
genome-wide association studies (GWAS) with independent replication, totalling 13,656 CRC 
cases and 21,667 controls of European ancestry. The combined analysis identified a new risk 
association for CRC at 2q35 marked by rs992157 (P = 3.15 × 10
−8
,
 
odds ratio = 1.10, 95% 
confidence interval = 1.06-1.13), which is intronic to PNKD and TMBIM1. Intriguingly this 
susceptibility SNP is in strong LD (r
2
 = 0.90, D’ = 0.96) with the previously discovered GWAS 
SNP rs2382817 for inflammatory bowel disease (IBD). Following on from this observation we 
examined for pleiotropy, or shared genetic susceptibility, between CRC and the 200 established 
IBD risk loci, identifying an additional 11 significant associations (FDR < 0.05). Our findings 
provide further insight into the biological basis of inherited genetic susceptibility to CRC, and 
identify risk factors that may influence the development of both CRC and IBD.  
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INTRODUCTION 
 
Colorectal cancer (CRC), a leading cause of cancer-related death worldwide, has a heritable basis 
(1, 2). Recent genome-wide association studies (GWAS) have successfully identified a number of 
common single-nucleotide polymorphisms (SNPs) influencing CRC risk thereby vindicating the 
assertion that part of the heritable risk is polygenic (3-7). These studies have also provided insights 
into the biology of CRC, highlighting the importance of bone morphogenetic protein signalling 
pathway genes (BMP2, BMP4, GREM1 and SMAD7) (4, 5), candidate genes (CDH1), as well as 
genes not previously implicated in CRC (POLD3, TERC, CDKN1A, VIT1A and SHROOM2) (6, 7). 
It is well established that inflammatory bowel disease (IBD), which primarily presents as Crohn’s 
disease or ulcerative colitis, is associated with an increased CRC risk (8-11). Despite IBD being 
strongly heritable (12), little evidence for shared genetic susceptibility or differential effects of 
genetic variation on IBD and CRC risk has been reported, although the presumption is that the 
direction of effect will be consistent between both diseases. 
 
A failure to uncover pleiotropy may be reflective of a lack of power of CRC GWAS conducted thus 
far. Indeed statistical modelling of GWAS data shows that although 19% of the heritability of CRC 
can be ascribed to common variation, only 10% of this is explained by currently identified risk 
SNPs (13). To empower the identification of new CRC susceptibility SNPs in persons of European 
ancestry, we conducted a genome-wide meta-analysis of a previously unreported GWAS with six 
published datasets in addition to independent replication totalling 13,810 cases and 21,754 controls.  
 
We report the identification of a new CRC risk association which also impacts on IBD risk. 
Extending our analysis to established IBD loci, we provide evidence of shared genetic susceptibility 
between CRC and IBD at 11 additional loci. 
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RESULTS 
 
Primary GWAS 
In the primary scan (termed the FIN GWAS), 1,172 CRC cases ascertained through the Finnish 
CRC collection and Finnish Cancer Registry were analysed with control data on 8,266 individuals 
from the FINRISK, Health2000, Finnish Twin Cohort and Helsinki Birth Cohort Study cohorts. 
After applying strict quality control criteria, 283,906 autosomal SNPs were available for association 
with CRC risk. A quantile-quantile (Q-Q) plot of observed versus expected χ
2
-test statistics showed 
little evidence for an inflation of test statistics, thereby excluding the possibility of substantive 
hidden population substructure, cryptic relatedness among subjects or differential genotype calling 
(inflation factor λ = 1.07). 
 
Meta-analysis 
We performed a meta-analysis of our primary scan data with six other non-overlapping GWAS of 
European ancestry (CCFR1, CCFR2, COIN, UK1, Scotland1, VQ58), which have been previously 
reported (14). To maximise the prospects of identifying novel risk variants, we imputed the data 
with a merged reference panel using Sequencing Initiative Suomi (for the FIN data) or UK10K (for 
the UK data) in addition to 1000 Genomes Project data. After quality control procedures, over 10 
million variants, including over 1 million insertion-deletions, were analysed in 8,749 cases and 
18,245 controls.  
 
Associations for the 37 previously established European CRC risk SNPs showed a direction of 
effect consistent with previously reported studies, with 10 of these SNPs having P < 5.0 × 10
−8
 in 
this meta-analysis (Supplementary Table 1). Excluding these known risk SNPs, together with those 
correlated with r
2
 > 0.8, from the meta-analysis two novel regions of linkage disequilibrium (LD), 
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marked by rs992157 and rs2383207, showed the strongest association with CRC at P < 1.0 × 10
−6
 
(Supplementary Table 2). 
 
To replicate these associations, we genotyped rs992157 and rs2383207 in an additional 5,061 CRC 
cases and 3,509 controls, with only rs992157 showing evidence for an association with CRC (P = 
0.023). In the combined analysis the association was significant at the genome-wide threshold (P = 
3.15 x 10
-8
; Figure 1). There was no variation due to heterogeneity (I
2
 = 0, Phet = 0.79). rs992157 is 
located at 2q35, and is intronic to two genes: paroxysmal nonkinesigenic dyskinesia (PNKD) on the 
forward strand, and transmembrane BAX inhibitor motif containing 1 (TMBIM1) on the reverse 
strand (Figure 2).  
 
Relationship between genotype and colorectal cancer phenotype 
Using data on microsatellite instability (MSI) status from the FIN (n = 1,146), COIN (n = 1,239) 
and NSCCG replication (n = 1,282) series, together with information on KRAS and BRAF mutation 
status in tumours in COIN, we explored the possibility that the association at rs992157 is restricted 
to a specific molecular subtype of CRC (Supplementary Table 3). There was no evidence of an 
association between these SNPs and any of the variables after adjusting for multiple testing (i.e. P > 
0.05). Additionally we observed no consistent association between age, sex or tumour site using 
data from the UK1, Scotland1, VQ58, COIN, and NSCCG series (Supplementary Table 3). 
 
Inflammatory bowel disease SNPs influence colorectal cancer  
Another association at 2q35 defined by rs2382817 has previously been shown to influence IBD risk 
(CRC meta P = 1.02 x 10
-5
), which is also intronic to PNKD and TMBIM1, and is in strong LD with 
rs992157 (r
2
 = 0.90, D’ = 0.96). Paradoxically, the risk for rs2382817 in IBD is inverse to the CRC 
association. Given the compelling evidence for an association between IBD and CRC we sought 
evidence for additional shared susceptibility between the two diseases. Specifically, we examined 
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the risk of CRC in our meta-analysis at 200 loci that have been shown in previous GWAS to affect 
IBD risk (15, 16) (Supplementary Table 4). A Q-Q plot of the observed CRC association P-values 
against the expected P-values for each of the 200 IBD risk SNPs showed significant over-dispersion 
(λ = 1.33, Figure 3). This observation is compatible with a genetic relationship between CRC and 
IBD.  
 
To account for multiple testing we imposed an FDR-adjusted P-value of 0.05 as being statistically 
significant. At this threshold, in addition to rs2382817, 11 IBD risk SNPs were associated with 
CRC risk (Table 1), of which five were positively associated with CRC risk, while the other seven 
displayed an inverse relationship. A number of these SNPs annotate genes with documented roles 
that are relevant to CRC development, such as Wnt-signalling (WNT4, (17)), tumour suppression 
(MAPKAPK5, FOXO1 (18, 19)) and cellular transformation (CDC42, CEBPB (20, 21)) (Table 1). 
We examined for an association between the genotype of these 12 SNPs and the molecular subtype 
of CRC, and found no evidence of a relationship (Supplementary Table 3). 
 
Functional effect prediction analysis 
The genomic region containing rs992157 is the site of active structure and has regulatory motifs for 
both enhancer and promotor function in multiple cell types (Figure 2). Moreover ChIP-seq data 
identifies over 122 transcription factors binding to the region, including CRC related transcription 
factors such as MYC, HNF4A and TCF7L2 (Supplementary Table 5). We also performed an eQTL 
analysis and found no significant relationship between the rs992157 genotype and PNKD and 
TMBIM1 expression in colorectal adenocarcinoma cells (Supplementary Table 6). The risk 
genotype was however associated with altered gene expression in other tissues, including 
lymphoblastoid cells (FDR P-value < 0.05, Supplementary Table 6). This apparent difference in 
eQTLs may be reflective of the differences in epigenetic profiles at 2q35 between CRC and 
lymphoblastoid cells (Figure 2). 
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To further investigate the relationship between CRC and IBD risk we performed eQTL analysis on 
the 12 IBD SNPs associated with CRC risk in the colorectal adenocarcinoma data, and found two 
significant relationships between rs174537 and the expression of fatty acid desaturase 2 (FADS2, 
FDR P-value = 3.28 x 10
-6
) and between rs516246 and fucosyltransferase 2 (FUT2, FDR P-value = 
2.08 x 10
-17
) (Supplementary Table 6). Additional evidence for these eQTLs was found in other 
tissues in the Geuvadis, Blood and GTEx databases (Supplementary Table 6). Similarly to 
rs992157, as reported above, rs2382817 is an eQTL for PNKD and TMBIM1 in both 
lymphoblastoid and whole blood tissues.  
 
Following on from this we investigated the presence of shared genetic pathways between CRC and 
IBD using the LENS pathway tool (22), which allows exploration of interactions between the gene 
products in proximity to the GWAS SNPs. Across the 594 CRC proteins and 1,574 IBD proteins, a 
network of 542 overlapping proteins was identified. Figure 4 shows the common network and 
interactions between key proteins. Of interest was the direction of association between the CRC 
SNPs with IBD risk. Pathways with evidence of enrichment (i.e. P < 0.001) with a consistent effect 
between CRC and IBD were involved in immune and inflammatory response, such as co-
stimulation by the CD28 family, Fc epsilon receptor signalling, and downstream B-cell receptor 
signalling. In contrast, the protein networks defined by reciprocal SNPs association for CRC and 
IBD were enriched for interleukin and calmodulin signalling. Pathways that were enriched in both, 
albeit involving different proteins, included those related to the adaptive immune response, cytokine 
signalling and interferon signalling (Supplementary Table 7).  
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DISCUSSION 
In this meta-analysis we combined seven independent GWAS, and have identified a risk locus for 
CRC risk at 2q35 marked by rs992157. Since this SNP is intronic to both PNKD and TMBIM1, and 
these are the only transcripts within the region of high LD, it is a plausible that the genetic basis of 
the 2q35 association for CRC is through functional effects on one of these genes a priori. This is 
coupled with the fact that rs992157 localises to a genomic region with regulatory function and the 
eQTL data showing allele-specific cis-regulatory relationship between SNP genotype and PNKD 
and TMBIM1 expression. Although speculative the long isoform of PNKD appears to function in a 
pathway to detoxify alpha-ketoaldehyde using glutathione as a cofactor (23). Since glutathione is 
essential for maintaining cellular redox status, reduced glutathione levels in cells through 
dysfunctional PNKD may lead to increasing oxidative stress levels, which have been linked to 
inflammation (24). TMBIM1 has been reported to have a role in regulating the level of Fas ligand 
(FasL) (25, 26), which mediates both apoptosis and inflammation (27). Therefore, both gene 
products indirectly contribute to the regulation of inflammation, a physiological process linked with 
the onset of IBD and CRC. 
 
Another SNP in the 2q35 locus (rs2382817), which is in strong LD with rs992157, has previously 
been shown to influence IBD risk (15). In addition, contemporaneous with our analysis, a recent 
study (28) has also found evidence, albeit not GWAS significant, for a relationship between 2q35 
variation and CRC risk (P = 7.0 x 10
-5
), additionally finding an inverse relationship with risk of 
IBD. The identified SNP, rs11676348, is correlated with both rs992157 and rs2382817 (LD metrics, 
r
2
 and D’ = 0.32, 0.65 and 0.33, 0.71 respectively). The opposing effects of the rs2382817-C allele 
with increased risk of CRC but decreased risk of IBD may initially appear paradoxical, given the 
increased risk of CRC associated with IBD. The risk of CRC in IBD increases with longer duration, 
extent of colitis and the degree of inflammation (11). The inflammatory response has been linked to 
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increased oxidative stress, and this oxidative state stimulates antioxidant defences that promote the 
survival pathways in cancer cells, favouring tumour proliferation (29). Nonetheless, these SNPs 
may indicate shared pathways in which there are opposing relationships between carcinogenesis and 
inflammation. 
 
Motivated by the observation that the 2q35 locus influences IBD risk, we sought additional 
evidence for a common genetic basis for both diseases by evaluating the CRC risk at previously 
established IBD loci (15, 16). While not formally significant globally, there was an over-
representation of association signals for CRC defined by the IBD risk SNPs. Through this analysis 
we identified potential risk variants for CRC mapped to regions in the proximity of genes encoding 
WNT4 and CDC42, previously shown to be involved in the risk of CRC (14); MAPKAPK5, a 
member of the MAPK family reported to regulate MYC protein levels (18); and the transcription 
factor CEBPB, found to be highly expressed in samples derived from CRC patients (21). Moreover 
our eQTL analysis on IBD SNPs showed altered expression of FADS2 and FUT2 genes in CRC 
tissues. Both the genes have previously been reported to have a role in the development of IBD (30, 
31) providing further evidence of possible shared genes. Further studies are required to delineate the 
genetic basis and implicate perturbation of a specific gene as the functional basis of the 
associations. Collectively these data are consistent with a degree of commonality in genetically-
defined pathways in the development between CRC and IBD, albeit that many of the associations 
have opposite effects. 
 
Considering the low prevalence of IBD in European populations (< 0.5%) (32), together with the 
observation that other SNPs that are strongly associated with risk of IBD were not associated with 
CRC, it is unlikely that sampling has biased our findings. Moreover if the association between these 
IBD SNPs and CRC was simply mediated by its association with IBD per se, we would have 
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expected directionality of the association to be identical but this was not the case for many of the 
SNPs. 
 
In summary, we have identified a new risk association for CRC which also influences IBD risk. Our 
association signals for CRC defined by other established IBD risk SNPs also serve to highlight the 
importance of shared gene pathways in the development of CRC and IBD. Deciphering the 
functional and biological basis of these SNPs associations has the potential to translate into a better 
understanding of the biological basis of how IBD transitions to CRC. Finally our analysis serves to 
illustrate that inter-relationships between diseases do not necessarily equate to consistent allelic 
architecture in risk, thus adding an extra layer of complexity to interpretation.  
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MATERIALS AND METHODS 
 
Ethics  
Collection of blood samples and clinico-pathological information from subjects was undertaken 
with informed consent and ethical review board approval at all sites in accordance with the tenets of 
the Declaration of Helsinki. 
 
Primary GWAS 
The Finnish GWAS (FIN) was based on 1,172 CRC cases and 8,266 cancer free controls 
ascertained through Finnish Hospitals (33) and through the Finnish Cancer Registry. Cases were 
genotyped using Illumina HumanOmni 2.5M8v1 according to the manufacturer’s 
recommendations. For controls, we made use of Illumina HumanHap 670k and 610k array data on 
individuals from the FINRISK (34), Health 2000 (35), Finnish Twin Cohort (36) and Helsinki Birth 
Cohort Studies (37). Individuals were excluded with: <90% successfully genotyped SNPs, 
discordant sex information, duplication or cryptic relatedness (identity by descent >0.2). We 
excluded SNPs from the analysis with: call rate <95%, MAF < 0.01, and departure from Hardy-
Weinberg equilibrium in controls at P < 10
−6
. The adequacy of the case-control matching and the 
possibility of differential genotyping of cases and controls were assessed using quantile-quantile 
(Q-Q) plots of test statistics. 
 
Published GWAS for meta-analysis 
We made use of six previously published GWAS: UK1 (CORGI study) (7) comprised 940 cases 
with colorectal neoplasia and 965 controls; Scotland1 (COGS study) (7) included 1,012 CRC cases 
and 1,012 controls; VQ58 comprised 1,800 CRC cases from the UK-based VICTOR and 
QUASAR2 adjuvant chemotherapy clinical trials (38) and 2,690 population control genotypes from 
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the Wellcome Trust Case Control Consortium 2 (WTCCC2) 1958 birth cohort (39); CCFR1 
comprised 1,290 familial CRC cases and 1,055 controls from the Colon Cancer Family Registry 
(CCFR) (40); CCFR2 included a further 796 cases from the CCFR and 2,236 controls from the 
Cancer Genetic Markers of Susceptibility (CGEMS) studies of breast and prostate cancer (41, 42); 
and the COIN GWAS (14) was based on 2,244 CRC cases ascertained through two independent 
Medical Research Council clinical trials of advanced/metastatic CRC (COIN and COIN-B) (43) and 
controls comprised 2,162 individuals from the UK Blood Service Control Group genotyped as part 
of the WTCCC2 (39). 
 
The VQ58, UK1 and Scotland1 GWAS series were genotyped using Illumina Hap300, Hap240S, 
Hap370, Hap550 or Omni2.5M arrays. 1958BC genotyping was performed as part of the WTCCC2 
study on Hap1.2M-Duo Custom arrays. The CCFR samples were genotyped using Illumina Hap1M, 
Hap1M-Duo or Omni-express arrays. CGEMS samples were genotyped using Illumina Hap300 and 
Hap240 or Hap550 arrays. The COIN cases were genotyped using Affymetrix Axiom Arrays and 
the Blood Service controls were genotyped using Affymetrix 6.0 arrays. After applying the same 
quality control as that performed for FIN, data on 8,749 CRC cases and 18,245 controls were 
available for the meta-analysis. 
 
The adequacy of the case-control matching and possibility of differential genotyping of cases and 
controls was assessed using Q-Q plots of test statistics. λGC values (44) for the UK1, Scotland1, 
VQ58, CCFR1, CCFR2 and COIN studies were 1.02, 1.01, 1.01, 1.02, 1.03 and 1.05 respectively. 
Any ethnic outliers or individuals identified as related were excluded. 
 
Replication series  
5,061 CRC cases from the National Study of Colorectal Cancer Genetics (NSCCG) (45) were 
genotyped. Controls (n = 3,509) were from NSCCG and the Genetic Lung Cancer Predisposition 
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Study (GELCAPS) (46). None of the controls had a known history of malignancy at ascertainment. 
All subjects were British residents with self-reported European ethnicity and there were no obvious 
demographic differences between cases and controls. DNA was extracted from EDTA-venous 
blood samples using conventional methodologies and PicoGreen quantified (Invitrogen 
Corporation, Carlsbad, CA, USA). Genotyping of two SNPs was conducted using KASPar 
competitive allele-specific PCR chemistry (LGC, Hoddesdon, UK; primer sequences and conditions 
available on request). To monitor quality control, duplicate samples were included in assays, and 
concordance between duplicate samples was >99%.  
 
Imputation and meta-analysis 
Analyses were undertaken using R (v3.02) (47) and PLINK (v1.9) (48) software. Phasing of GWAS 
SNP genotypes was performed using SHAPEIT (v2.r644 and v2.r790 for FIN) (49). Prediction of 
the untyped SNPs was carried out using IMPUTE (v2.3.1) (50). The FIN dataset used a merged 
reference panel based on data from the 1000 Genomes Project (Phase 1 v3) (51) together with an 
additional population matched reference panel of 3,882 Sequencing Initiative Suomi (SISu) 
haplotypes. The UK samples used a merged reference panel using data from the 1000 Genomes 
Project and UK10K (April 2014 release). The fidelity of imputation, as assessed by the concordance 
between imputed and sequenced SNPs, was examined in a subset of 200 UK cases (14). The 
association between each SNP and the risk of CRC was assessed by a frequentist association test 
under an additive model, using SNPTEST (v2.5.1) (52), utilising the genotype probabilities from 
IMPUTE where a SNP was not directly typed. Population stratification was controlled in the FIN 
samples using sex and six principal components. Association meta-analyses only included markers 
with info scores >0.8, imputed call rates/SNP >0.9 and MAFs >0.005. Meta-analyses were carried 
out using META (v1.6) (53). We calculated Cochran's Q statistic to test for heterogeneity and the I
2
 
statistic to quantify the proportion of the total variation that was caused by heterogeneity (54). I
2 
values ≥75% are considered characteristic of large heterogeneity (54). 
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Characterisation of cancer phenotype  
Associations by sex, age and clinico-pathological phenotypes were examined by logistic regression. 
MSI status was determined using BAT25 and BAT26 markers, and samples showing ≥ 5 novel 
alleles when compared with normal DNA at either or both markers were assigned as MSI-H 
(corresponding to MSI-high) (55). Tumours were screened for KRAS codons 12, 13, and 61 and 
BRAF codon 600 mutations by pyrosequencing (43). Additionally, KRAS (all three codons) and 
BRAF (codons 594 and 600) were screened for mutations by MALDI-TOF mass array (Sequenom, 
San Diego, CA, USA) (56). Differences between the various sites of the tumour (colonic [ICD-
9:153], rectal [ICD-9:154.1], and recto sigmoid junction [ICD9:154.0]) were also analysed. 
 
Functional prediction 
To explore epigenetic profiles of genomic location associated with CRC, we used ENCODE histone 
modification data, HaploReg and RegulomeDB (57, 58) to examine whether any of the SNPs or 
their proxies (i.e. r
2
 > 0.8 in the 1000 Genomes EUR reference panel) annotate transcription factor 
binding or enhancer elements. Additionally we made use of ChIP-seq data on the LoVo CRC cell 
line (59). We used ChromHMM to integrate DNAse, H3K4me3, H3K4me1, H3K27ac, Pol2 and 
CTCF states from the CRC cell line HCT116 using a multivariate Hidden Markov Model (60). 
ChromHMM tracks for lymphoblastoid cells were obtained from ENCODE (61). We assessed 
sequence conservation using: PhastCons (62) (>0.3 indicative of conservation) and Genomic 
Evolutionary Rate Profiling (GERP) (63) (>2 indicative of conservation). SNAP plots were created 
using the visPIG tool (64). 
 
eQTL analysis 
To examine for a relationship between SNP genotype and mRNA expression in CRC we analysed 
Tumor Cancer Genome Atlas (TCGA) RNA-seq expression and Affymetrix 6.0 SNP data (dbGaP 
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accession number: phs000178.v7.p6) on 416 colorectal adenocarcinoma samples (65). Association 
between normalised RNA counts per-gene and SNP genotype was quantified using the Kruskal-
Wallis trend test. To look for a relationship between SNP genotype and expression levels in other 
tissues we used publicly available expression data generated from the MuTHER (66), eQTL Blood 
Browser (67), GTEx (68) and Geuvadis/1000 Genomes (69) resources. For the Geuvadis data, the 
relationship between SNPs and expression of genes located within 1 Mb was analysed using the 
Matrix eQTL (70) package under a linear model. When the SNPs were not directly typed, a proxy 
SNP was used (r
2
 ≥ 0.8). In all the datasets, eQTL results were included where FDR P < 0.05  
 
Relationship between established risk SNPs for inflammatory bowel disease and colorectal 
cancer 
To investigate pleiotropic (shared genetic susceptibility) between CRC and inflammatory bowel 
disease (IBD), we examined the 201 SNPs identified in GWAS that have been shown to affect IBD 
risk (15, 16). One SNP (rs71559680) is an indel that was not present in the CRC genotyping arrays 
or the reference panels, and was thus removed from the analysis. We obtained the lead SNPs from 
the IBD GWAS and extracted the P-values for the corresponding SNPs in our CRC meta-analysis.  
 
Pathway analysis  
To investigate the possibility of shared genetic susceptibility between CRC and IBD, we performed 
pathway analysis. First, we selected the two closest coding genes for the leading SNPs in each 
GWAS and then performed pathway analysis using LENS tool (22), which identifies gene product 
and protein-protein interactions from HPRD (71) and BioGRID (72). Enrichment of pathways was 
assessed using Fisher’s exact test, comparing the overlap of the genes in the network with the genes 
in the pathway. Pathway data was obtained from REACTOME (73). Cytoscape was used to perform 
network analyses (74), and the Hive Plot was drawn using HiveR 
(academic.depauw.edu/~hanson/HiveR/HiveR.html). 
 at Edinburgh U
niversity on A
pril 1, 2016
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
18 
 
 
ACKNOWLEDGEMENTS 
We would like to thank Amit Sud for his critical reading of the manuscript. We are grateful to all 
individuals who participated in the various studies. This study made use of genotyping data from 
the 1958 Birth Cohort, kindly made available by the Wellcome Trust Case Control Consortium 2. A 
full list of the investigators who contributed to the generation of the data is available at 
http://www.wtccc.org.uk/. The results published here are in whole or part based upon data 
generated by The Cancer Genome Atlas pilot project established by the NCI and NHGRI. 
Information about TCGA and the investigators and institutions that constitute the TCGA research 
network can be found at http://cancergenome.nih.gov/. 
In Finland, this work was supported by grants from the Academy of Finland [Finnish Center of 
Excellence Program 2012–2017, 250345], the Jane and Aatos Erkko Foundation, the Finnish 
Cancer Society [personal grant to K.P.], the European Research Council [ERC; 268648], the Sigrid 
Juselius Foundation, SYSCOL, the Nordic Information for Action eScience Center (NIASC), the 
Nordic Center of Excellence financed by NordForsk [project 62721, personal grant to K.P.] and 
State Research Funding of Kuopio University Hospital [B1401]. We acknowledge the 
computational resources provided by the ELIXIR node, hosted at the CSC–IT Center for Science, 
Finland, and funded by the Academy of Finland [grants 271642 and 263164], the Ministry of 
Education and Culture, Finland. V.S. was supported by the Finnish Academy [grant number 
139635]. Sample collection and genotyping in the Finnish Twin Cohort has been supported by the 
Wellcome Trust Sanger Institute, ENGAGE – European Network for Genetic and Genomic 
Epidemiology, FP7-HEALTH-F4-2007 [grant agreement number 201413], the National Institute of 
Alcohol Abuse and Alcoholism [grants AA-12502 and AA-00145 to Richard J Rose and 
K02AA018755 to Danielle M Dick] and the Academy of Finland [grants 100499, 205585, 265240 
and 263278 to J.K.]. 
 at Edinburgh U
niversity on A
pril 1, 2016
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
19 
 
At the Institute of Cancer Research, this work was supported by Cancer Research UK 
[C1298/A8362 - Bobby Moore Fund for Cancer Research UK]. Additional support was provided by 
the National Cancer Research Network and the NHS via the Biological Research Centre of the 
National Institute for Health Research at the Royal Marsden Hospital NHS Trust. In Edinburgh the 
work was supported by Programme Grant funding from Cancer Research UK [C348/A12076]. In 
Oxford additional funding was provided by the Oxford Comprehensive Biomedical Research 
Centre [to C.P. and I.P.M.T.] and the EU FP7 CHIBCHA grant [I.P.M.T.]. Core infrastructure 
support to the Wellcome Trust Centre for Human Genetics, Oxford was provided by grant 
[090532/Z/09/Z]. We are grateful to many colleagues within UK Clinical Genetics Departments 
(for CORGI) and to many collaborators who participated in the VICTOR and QUASAR2 trials. We 
also thank colleagues from the UK National Cancer Research Network (for NSCCG). Support from 
the European Union [FP7/207-2013, grant 258236] and FP7 collaborative project SYSCOL and 
COST Action in the UK is also acknowledged [BM1206]. The COIN and COIN-B trials were 
funded by Cancer Research UK and the Medical Research Council and were conducted with the 
support of the National Institute of Health Research Cancer Research Network. COIN and COIN-B 
translational studies were supported by the Bobby Moore Fund from Cancer Research UK, 
Tenovus, the Kidani Trust, Cancer Research Wales and the National Institute for Social Care and 
Health Research Cancer Genetics Biomedical Research Unit (2011-2014) [all awarded to J.P.C.]. 
N.A.A., B.F.M. and S.M.W. were funded and supported by KFSHRC. 
The work of the Colon Cancer Family Registry (CCFR) was supported by from the National Cancer 
Institute [grant UM1 CA167551], National Institutes of Health and through cooperative agreements 
with the following CCFR centres: Australasian Colorectal Cancer Family Registry [U01 
CA074778, U01/U24 CA097735], USC Consortium Colorectal Cancer Family Registry [U01/U24 
CA074799], Mayo Clinic Cooperative Familial Registry for Colon Cancer Studies [U01/U24 
CA074800], Ontario Familial Colorectal Cancer Registry [U01/U24 CA074783], Seattle Colorectal 
 at Edinburgh U
niversity on A
pril 1, 2016
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
20 
 
Cancer Family Registry [U01/U24 CA074794], and University of Hawaii Colorectal Cancer Family 
Registry [U01/U24 CA074806].  
The CCFR Illumina GWAS was supported by funding from the National Cancer Institute, National 
Institutes of Health [U01 CA122839 and R01 CA143237 to G.C.]. Seattle CCFR research was also 
supported by the Cancer Surveillance System of the Fred Hutchinson Cancer Research Center 
[Control Nos. N01-CN-67009 (1996-2003), N01-PC-35142 (2003-2010)] and the Surveillance, 
Epidemiology and End Results (SEER) Program of the National Cancer Institute [Contract No. 
HHSN2612013000121 (2010-2017)] with additional support from the Fred Hutchinson Cancer 
Research Center. The collection of cancer incidence data for the State of Hawai’i used in this study 
was supported by the Hawai‘i Department of Health as part of the statewide cancer reporting 
program mandated by Hawai‘i Revised Statutes; the National Cancer Institute’s Surveillance, 
Epidemiology and End Results Program (SEER) awarded to the University of Hawai‘i [Control 
Nos. N01-PC-67001 (1996-2003), N01-PC-35137 (2003-2010), Contract Nos. 
HHSN26120100037C (2010-2013), HHSN261201300009I (2010-current)]. The ideas and opinions 
expressed herein are those of the author(s) and endorsement by the State of Hawai‘i, Department of 
Health, the National Cancer Institute, SEER Program or their Contractors and Subcontractors is not 
intended nor should be inferred. The collection of cancer incidence data used in this study was 
supported by the California Department of Public Health as part of the statewide cancer reporting 
program mandated by California Health and Safety Code Section 103885; the National Cancer 
Institute’s Surveillance, Epidemiology and End Results Program [under contract 
HHSN261201000035C] awarded to the University of Southern California, and [contract 
HHSN261201000034C] awarded to the Public Health Institute; and the Centers for Disease Control 
and Prevention’s National Program of Cancer Registries, under agreement [U58DP003862-01] 
awarded to the California Department of Public Health. The ideas and opinions expressed herein are 
those of the author(s) and endorsement by the State of California, Department of Public Health the 
National Cancer Institute, and the Centers for Disease Control and Prevention or their Contractors 
 at Edinburgh U
niversity on A
pril 1, 2016
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
21 
 
and Subcontractors is not intended nor should be inferred. The content of this manuscript does not 
necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating 
centers in the CCFR, nor does mention of trade names, commercial products, or organizations 
imply endorsement by the US Government or the CCFR. 
 
CONFLICT OF INTEREST STATEMENT 
None declared. 
 
 
 at Edinburgh U
niversity on A
pril 1, 2016
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
22 
 
REFERENCES 
 
1 Jiao, S., Peters, U., Berndt, S., Brenner, H., Butterbach, K., Caan, B.J., Carlson, C.S., Chan, A.T., 
Chang-Claude, J., Chanock, S. et al. (2014) Estimating the heritability of colorectal cancer. Human 
molecular genetics, 23, 3898-3905. 
2 Peters, U., Jiao, S., Schumacher, F.R., Hutter, C.M., Aragaki, A.K., Baron, J.A., Berndt, S.I., 
Bezieau, S., Brenner, H., Butterbach, K. et al. (2013) Identification of Genetic Susceptibility Loci for 
Colorectal Tumors in a Genome-Wide Meta-analysis. Gastroenterology, 144, 799-807 e724. 
3 Whiffin, N. and Houlston, R.S. (2014) Architecture of inherited susceptibility to colorectal cancer: a 
voyage of discovery. Genes, 5, 270-284. 
4 Tomlinson, I.P., Carvajal-Carmona, L.G., Dobbins, S.E., Tenesa, A., Jones, A.M., Howarth, K., 
Palles, C., Broderick, P., Jaeger, E.E., Farrington, S. et al. (2011) Multiple common susceptibility variants 
near BMP pathway loci GREM1, BMP4, and BMP2 explain part of the missing heritability of colorectal 
cancer. PLoS genetics, 7, e1002105. 
5 Broderick, P., Carvajal-Carmona, L., Pittman, A.M., Webb, E., Howarth, K., Rowan, A., Lubbe, S., 
Spain, S., Sullivan, K., Fielding, S. et al. (2007) A genome-wide association study shows that common 
alleles of SMAD7 influence colorectal cancer risk. Nat Genet, 39, 1315-1317. 
6 Dunlop, M.G., Dobbins, S.E., Farrington, S.M., Jones, A.M., Palles, C., Whiffin, N., Tenesa, A., 
Spain, S., Broderick, P., Ooi, L.Y. et al. (2012) Common variation near CDKN1A, POLD3 and SHROOM2 
influences colorectal cancer risk. Nat Genet, 44, 770-776. 
7 Houlston, R.S., Cheadle, J., Dobbins, S.E., Tenesa, A., Jones, A.M., Howarth, K., Spain, S.L., 
Broderick, P., Domingo, E., Farrington, S. et al. (2010) Meta-analysis of three genome-wide association 
studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33. Nat Genet, 
42, 973-977. 
8 Ullman, T.A. and Itzkowitz, S.H. (2011) Intestinal inflammation and cancer. Gastroenterology, 140, 
1807-1816. 
9 Rizzo, A., Pallone, F., Monteleone, G. and Fantini, M.C. (2011) Intestinal inflammation and 
colorectal cancer: a double-edged sword? World journal of gastroenterology : WJG, 17, 3092-3100. 
 at Edinburgh U
niversity on A
pril 1, 2016
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
23 
 
10 O'Connor, P.M., Lapointe, T.K., Beck, P.L. and Buret, A.G. (2010) Mechanisms by which 
inflammation may increase intestinal cancer risk in inflammatory bowel disease. Inflammatory bowel 
diseases, 16, 1411-1420. 
11 Xie, J. and Itzkowitz, S.H. (2008) Cancer in inflammatory bowel disease. World journal of 
gastroenterology : WJG, 14, 378-389. 
12 Bengtson, M.-B., Solberg, C., Aamodt, G., Sauar, J., Jahnsen, J., Moum, B., Lygren, I. and Vatn, 
M.H. (2009) Familial aggregation in Crohn's disease and ulcerative colitis in a Norwegian population-based 
cohort followed for ten years. Journal of Crohn's and Colitis, 3, 92-99. 
13 Frampton, M.J., Law, P., Litchfield, K., Morris, E.J., Kerr, D., Turnbull, C., Tomlinson, I.P. and 
Houlston, R.S. (2015) Implications of polygenic risk for personalised colorectal cancer screening. Annals of 
oncology : official journal of the European Society for Medical Oncology / ESMO, in press. 
14 Al-Tassan, N.A., Whiffin, N., Hosking, F.J., Palles, C., Farrington, S.M., Dobbins, S.E., Harris, R., 
Gorman, M., Tenesa, A., Meyer, B.F. et al. (2015) A new GWAS and meta-analysis with 1000Genomes 
imputation identifies novel risk variants for colorectal cancer. Scientific reports, 5, 10442. 
15 Jostins, L., Ripke, S., Weersma, R.K., Duerr, R.H., McGovern, D.P., Hui, K.Y., Lee, J.C., Schumm, 
L.P., Sharma, Y., Anderson, C.A. et al. (2012) Host-microbe interactions have shaped the genetic 
architecture of inflammatory bowel disease. Nature, 491, 119-124. 
16 Liu, J.Z., van Sommeren, S., Huang, H., Ng, S.C., Alberts, R., Takahashi, A., Ripke, S., Lee, J.C., 
Jostins, L., Shah, T. et al. (2015) Association analyses identify 38 susceptibility loci for inflammatory bowel 
disease and highlight shared genetic risk across populations. Nat Genet, 47, 979-986. 
17 Bernard, P., Fleming, A., Lacombe, A., Harley, V.R. and Vilain, E. (2008) Wnt4 inhibits beta-
catenin/TCF signalling by redirecting beta-catenin to the cell membrane. Biology of the cell / under the 
auspices of the European Cell Biology Organization, 100, 167-177. 
18 Kress, T.R., Cannell, I.G., Brenkman, A.B., Samans, B., Gaestel, M., Roepman, P., Burgering, B.M., 
Bushell, M., Rosenwald, A. and Eilers, M. (2011) The MK5/PRAK kinase and Myc form a negative 
feedback loop that is disrupted during colorectal tumorigenesis. Molecular cell, 41, 445-457. 
 at Edinburgh U
niversity on A
pril 1, 2016
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
24 
 
19 Gao, F. and Wang, W. (2015) MicroRNA-96 promotes the proliferation of colorectal cancer cells 
and targets tumor protein p53 inducible nuclear protein 1, forkhead box protein O1 (FOXO1) and FOXO3a. 
Molecular medicine reports, 11, 1200-1206. 
20 Stengel, K. and Zheng, Y. (2011) Cdc42 in oncogenic transformation, invasion, and tumorigenesis. 
Cellular signalling, 23, 1415-1423. 
21 Birkenkamp-Demtroder, K., Mansilla, F., Sorensen, F.B., Kruhoffer, M., Cabezon, T., Christensen, 
L.L., Aaltonen, L.A., Verspaget, H.W. and Orntoft, T.F. (2007) Phosphoprotein Keratin 23 accumulates in 
MSS but not MSI colon cancers in vivo and impacts viability and proliferation in vitro. Molecular oncology, 
1, 181-195. 
22 Handen, A. and Ganapathiraju, M.K. (2015) LENS: web-based lens for enrichment and network 
studies of human proteins. BMC Med Genomics, 8 Suppl 4, S2. 
23 Shen, Y., Lee, H.Y., Rawson, J., Ojha, S., Babbitt, P., Fu, Y.H. and Ptacek, L.J. (2011) Mutations in 
PNKD causing paroxysmal dyskinesia alters protein cleavage and stability. Human molecular genetics, 20, 
2322-2332. 
24 Reuter, S., Gupta, S.C., Chaturvedi, M.M. and Aggarwal, B.B. (2010) Oxidative stress, 
inflammation, and cancer: how are they linked? Free radical biology & medicine, 49, 1603-1616. 
25 Rojas-Rivera, D. and Hetz, C. (2015) TMBIM protein family: ancestral regulators of cell death. 
Oncogene, 34, 269-280. 
26 Shukla, S., Fujita, K., Xiao, Q., Liao, Z., Garfield, S. and Srinivasula, S.M. (2011) A shear stress 
responsive gene product PP1201 protects against Fas-mediated apoptosis by reducing Fas expression on the 
cell surface. Apoptosis, 16, 162-173. 
27 O'Connell, J., Houston, A., Bennett, M.W., O'Sullivan, G.C. and Shanahan, F. (2001) Immune 
privilege or inflammation? Insights into the Fas ligand enigma. Nature medicine, 7, 271-274. 
28 Khalili, H., Gong, J., Brenner, H., Austin, T.R., Hutter, C.M., Baba, Y., Baron, J.A., Berndt, S.I., 
Bezieau, S., Caan, B. et al. (2015) Identification of a Common Variant with Potential Pleiotropic Effect on 
Risk of Inflammatory Bowel Disease and Colorectal Cancer. Carcinogenesis, in press. 
29 Guina, T., Biasi, F., Calfapietra, S., Nano, M. and Poli, G. (2015) Inflammatory and redox reactions 
in colorectal carcinogenesis. Annals of the New York Academy of Sciences, 1340, 95-103. 
 at Edinburgh U
niversity on A
pril 1, 2016
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
25 
 
30 McGovern, D.P., Jones, M.R., Taylor, K.D., Marciante, K., Yan, X., Dubinsky, M., Ippoliti, A., 
Vasiliauskas, E., Berel, D., Derkowski, C. et al. (2010) Fucosyltransferase 2 (FUT2) non-secretor status is 
associated with Crohn's disease. Human molecular genetics, 19, 3468-3476. 
31 Costea, I., Mack, D.R., Lemaitre, R.N., Israel, D., Marcil, V., Ahmad, A. and Amre, D.K. (2014) 
Interactions between the dietary polyunsaturated fatty acid ratio and genetic factors determine susceptibility 
to pediatric Crohn's disease. Gastroenterology, 146, 929-931. 
32 Molodecky, N.A., Soon, I.S., Rabi, D.M., Ghali, W.A., Ferris, M., Chernoff, G., Benchimol, E.I., 
Panaccione, R., Ghosh, S., Barkema, H.W. et al. (2012) Increasing Incidence and Prevalence of the 
Inflammatory Bowel Diseases With Time, Based on Systematic Review. Gastroenterology, 142, 46-54.e42. 
33 Aaltonen, L.A., Salovaara, R., Kristo, P., Canzian, F., Hemminki, A., Peltomaki, P., Chadwick, R.B., 
Kaariainen, H., Eskelinen, M., Jarvinen, H. et al. (1998) Incidence of hereditary nonpolyposis colorectal 
cancer and the feasibility of molecular screening for the disease. N Engl J Med, 338, 1481-1487. 
34 Vaara, S., Nieminen, M.S., Lokki, M.L., Perola, M., Pussinen, P.J., Allonen, J., Parkkonen, O. and 
Sinisalo, J. (2012) Cohort Profile: the Corogene study. Int J Epidemiol, 41, 1265-1271. 
35 Kristiansson, K., Perola, M., Tikkanen, E., Kettunen, J., Surakka, I., Havulinna, A.S., Stančáková, 
A., Barnes, C., Widen, E., Kajantie, E. et al. (2012) Genome-Wide Screen for Metabolic Syndrome 
Susceptibility Loci Reveals Strong Lipid Gene Contribution But No Evidence for Common Genetic Basis for 
Clustering of Metabolic Syndrome Traits. Circulation: Cardiovascular Genetics, 5, 242-249. 
36 Kettunen, J., Tukiainen, T., Sarin, A.P., Ortega-Alonso, A., Tikkanen, E., Lyytikainen, L.P., Kangas, 
A.J., Soininen, P., Wurtz, P., Silander, K. et al. (2012) Genome-wide association study identifies multiple 
loci influencing human serum metabolite levels. Nat Genet, 44, 269-276. 
37 Eriksson, J.G. (2011) Early growth and coronary heart disease and type 2 diabetes: findings from the 
Helsinki Birth Cohort Study (HBCS). The American journal of clinical nutrition, 94, 1799S-1802S. 
38 Midgley, R.S., McConkey, C.C., Johnstone, E.C., Dunn, J.A., Smith, J.L., Grumett, S.A., Julier, P., 
Iveson, C., Yanagisawa, Y., Warren, B. et al. (2010) Phase III randomized trial assessing rofecoxib in the 
adjuvant setting of colorectal cancer: final results of the VICTOR trial. J Clin Oncol, 28, 4575-4580. 
39 Power, C. and Elliott, J. (2006) Cohort profile: 1958 British birth cohort (National Child 
Development Study). Int J Epidemiol, 35, 34-41. 
 at Edinburgh U
niversity on A
pril 1, 2016
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
26 
 
40 Newcomb, P.A., Baron, J., Cotterchio, M., Gallinger, S., Grove, J., Haile, R., Hall, D., Hopper, J.L., 
Jass, J., Le Marchand, L. et al. (2007) Colon Cancer Family Registry: an international resource for studies of 
the genetic epidemiology of colon cancer. Cancer Epidemiol Biomarkers Prev, 16, 2331-2343. 
41 Hunter, D.J., Kraft, P., Jacobs, K.B., Cox, D.G., Yeager, M., Hankinson, S.E., Wacholder, S., Wang, 
Z., Welch, R., Hutchinson, A. et al. (2007) A genome-wide association study identifies alleles in FGFR2 
associated with risk of sporadic postmenopausal breast cancer. Nat Genet, 39, 870-874. 
42 Yeager, M., Orr, N., Hayes, R.B., Jacobs, K.B., Kraft, P., Wacholder, S., Minichiello, M.J., 
Fearnhead, P., Yu, K., Chatterjee, N. et al. (2007) Genome-wide association study of prostate cancer 
identifies a second risk locus at 8q24. Nat Genet, 39, 645-649. 
43 Maughan, T.S., Adams, R.A., Smith, C.G., Meade, A.M., Seymour, M.T., Wilson, R.H., 
Idziaszczyk, S., Harris, R., Fisher, D., Kenny, S.L. et al. (2011) Addition of cetuximab to oxaliplatin-based 
first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised 
phase 3 MRC COIN trial. Lancet, 377, 2103-2114. 
44 Clayton, D.G., Walker, N.M., Smyth, D.J., Pask, R., Cooper, J.D., Maier, L.M., Smink, L.J., Lam, 
A.C., Ovington, N.R., Stevens, H.E. et al. (2005) Population structure, differential bias and genomic control 
in a large-scale, case-control association study. Nat Genet, 37, 1243-1246. 
45 Penegar, S., Wood, W., Lubbe, S., Chandler, I., Broderick, P., Papaemmanuil, E., Sellick, G., Gray, 
R., Peto, J. and Houlston, R. (2007) National study of colorectal cancer genetics. Br J Cancer, 97, 1305-
1309. 
46 Eisen, T., Matakidou, A., Houlston, R. and Consortium, G. (2008) Identification of low penetrance 
alleles for lung cancer: the GEnetic Lung CAncer Predisposition Study (GELCAPS). BMC cancer, 8, 244. 
47 R Core Team 2013. (Accessed 01/12/2014) R: A language and environment for statistical 
computing. . R Foundation for Statistical Computing, Vienna, Austria. URL http://www.R-project.org/ (Date 
of access 01/12/2014);, in press. 
48 Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M.A., Bender, D., Maller, J., Sklar, P., 
de Bakker, P.I., Daly, M.J. et al. (2007) PLINK: a tool set for whole-genome association and population-
based linkage analyses. American journal of human genetics, 81, 559-575. 
 at Edinburgh U
niversity on A
pril 1, 2016
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
27 
 
49 Delaneau, O., Marchini, J. and Zagury, J.F. (2012) A linear complexity phasing method for 
thousands of genomes. Nature methods, 9, 179-181. 
50 Howie, B.N., Donnelly, P. and Marchini, J. (2009) A flexible and accurate genotype imputation 
method for the next generation of genome-wide association studies. PLoS genetics, 5, e1000529. 
51 The 1000 Genomes Project Consortium. (2012) An integrated map of genetic variation from 1,092 
human genomes. Nature, 491, 56-65. 
52 Marchini, J., Howie, B., Myers, S., McVean, G. and Donnelly, P. (2007) A new multipoint method 
for genome-wide association studies by imputation of genotypes. Nat Genet, 39, 906-913. 
53 Liu, J.Z., Tozzi, F., Waterworth, D.M., Pillai, S.G., Muglia, P., Middleton, L., Berrettini, W., 
Knouff, C.W., Yuan, X., Waeber, G. et al. (2010) Meta-analysis and imputation refines the association of 
15q25 with smoking quantity. Nat Genet, 42, 436-440. 
54 Higgins, J.P. and Thompson, S.G. (2002) Quantifying heterogeneity in a meta-analysis. Statistics in 
medicine, 21, 1539-1558. 
55 Boland, C.R., Thibodeau, S.N., Hamilton, S.R., Sidransky, D., Eshleman, J.R., Burt, R.W., Meltzer, 
S.J., Rodriguez-Bigas, M.A., Fodde, R., Ranzani, G.N. et al. (1998) A National Cancer Institute Workshop 
on Microsatellite Instability for cancer detection and familial predisposition: development of international 
criteria for the determination of microsatellite instability in colorectal cancer. Cancer research, 58, 5248-
5257. 
56 Smith, C.G., Fisher, D., Claes, B., Maughan, T.S., Idziaszczyk, S., Peuteman, G., Harris, R., James, 
M.D., Meade, A., Jasani, B. et al. (2013) Somatic profiling of the epidermal growth factor receptor pathway 
in tumors from patients with advanced colorectal cancer treated with chemotherapy +/- cetuximab. Clin 
Cancer Res, 19, 4104-4113. 
57 Boyle, A.P., Hong, E.L., Hariharan, M., Cheng, Y., Schaub, M.A., Kasowski, M., Karczewski, K.J., 
Park, J., Hitz, B.C., Weng, S. et al. (2012) Annotation of functional variation in personal genomes using 
RegulomeDB. Genome research, 22, 1790-1797. 
58 Ward, L.D. and Kellis, M. (2012) HaploReg: a resource for exploring chromatin states, conservation, 
and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res, 40, D930-934. 
 at Edinburgh U
niversity on A
pril 1, 2016
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
28 
 
59 Yan, J., Enge, M., Whitington, T., Dave, K., Liu, J., Sur, I., Schmierer, B., Jolma, A., Kivioja, T., 
Taipale, M. et al. (2013) Transcription factor binding in human cells occurs in dense clusters formed around 
cohesin anchor sites. Cell, 154, 801-813. 
60 Jager, R., Migliorini, G., Henrion, M., Kandaswamy, R., Speedy, H.E., Heindl, A., Whiffin, N., 
Carnicer, M.J., Broome, L., Dryden, N. et al. (2015) Capture Hi-C identifies the chromatin interactome of 
colorectal cancer risk loci. Nature communications, 6, 6178. 
61 Ernst, J. and Kellis, M. (2012) ChromHMM: automating chromatin-state discovery and 
characterization. Nature methods, 9, 215-216. 
62 Duret, L. and Galtier, N. (2009) Biased gene conversion and the evolution of mammalian genomic 
landscapes. Annual review of genomics and human genetics, 10, 285-311. 
63 Davydov, E.V., Goode, D.L., Sirota, M., Cooper, G.M., Sidow, A. and Batzoglou, S. (2010) 
Identifying a high fraction of the human genome to be under selective constraint using GERP++. PLoS 
computational biology, 6, e1001025. 
64 Scales, M., Jager, R., Migliorini, G., Houlston, R.S. and Henrion, M.Y. (2014) visPIG--a web tool 
for producing multi-region, multi-track, multi-scale plots of genetic data. PloS one, 9, e107497. 
65 (Accessed 01/12/2014) The Cancer Genome Atlas http://cancergenome.nih.gov/, in press. 
66 Grundberg, E., Meduri, E., Sandling, J.K., Hedman, A.K., Keildson, S., Buil, A., Busche, S., Yuan, 
W., Nisbet, J., Sekowska, M. et al. (2013) Global analysis of DNA methylation variation in adipose tissue 
from twins reveals links to disease-associated variants in distal regulatory elements. American journal of 
human genetics, 93, 876-890. 
67 Westra, H.J., Peters, M.J., Esko, T., Yaghootkar, H., Schurmann, C., Kettunen, J., Christiansen, 
M.W., Fairfax, B.P., Schramm, K., Powell, J.E. et al. (2013) Systematic identification of trans eQTLs as 
putative drivers of known disease associations. Nat Genet, 45, 1238-1243. 
68 The GTEx Consortium. (2015) The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue 
gene regulation in humans. Science, 348, 648-660. 
69 Lappalainen, T., Sammeth, M., Friedlander, M.R., t Hoen, P.A., Monlong, J., Rivas, M.A., 
Gonzalez-Porta, M., Kurbatova, N., Griebel, T., Ferreira, P.G. et al. (2013) Transcriptome and genome 
sequencing uncovers functional variation in humans. Nature, 501, 506-511. 
 at Edinburgh U
niversity on A
pril 1, 2016
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
29 
 
70 Shabalin, A.A. (2012) Matrix eQTL: ultra fast eQTL analysis via large matrix operations. 
Bioinformatics, 28, 1353-1358. 
71 Keshava Prasad, T.S., Goel, R., Kandasamy, K., Keerthikumar, S., Kumar, S., Mathivanan, S., 
Telikicherla, D., Raju, R., Shafreen, B., Venugopal, A. et al. (2009) Human Protein Reference Database--
2009 update. Nucleic acids research, 37, D767-772. 
72 Chatr-Aryamontri, A., Breitkreutz, B.J., Heinicke, S., Boucher, L., Winter, A., Stark, C., Nixon, J., 
Ramage, L., Kolas, N., O'Donnell, L. et al. (2013) The BioGRID interaction database: 2013 update. Nucleic 
acids research, 41, D816-823. 
73 Croft, D., Mundo, A.F., Haw, R., Milacic, M., Weiser, J., Wu, G., Caudy, M., Garapati, P., Gillespie, 
M., Kamdar, M.R. et al. (2014) The Reactome pathway knowledgebase. Nucleic acids research, 42, D472-
477. 
74 Smoot, M.E., Ono, K., Ruscheinski, J., Wang, P.L. and Ideker, T. (2011) Cytoscape 2.8: new 
features for data integration and network visualization. Bioinformatics, 27, 431-432. 
 at Edinburgh U
niversity on A
pril 1, 2016
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
30 
 
FIGURE LEGENDS 
Figure 1: Forest plot of the odds ratios for the association between rs992157 and colorectal 
cancer. Studies were weighted according to the inverse of the variance of the log of the OR. 
Horizontal lines: 95% confidence intervals (95% CI). Box: OR point estimate; its area is 
proportional to the weight of the study. Diamond: overall summary estimate, with confidence 
interval given by its width. Vertical line: null value (OR = 1.0). 
 
Figure 2: Regional plot of association results and recombination rates for the 2q35 locus. In 
the panel, −log10 P values (y axis) of the SNPs are shown according to their chromosomal positions 
(x axis). The top SNP is shown as a large triangle and is labelled by its rsID. The colour intensity of 
each symbol reflects the extent of LD with the top SNP: white (r
2
 = 0) through to dark red (r
2
 = 
1.0), with r
2
 estimated from the 1000 Genomes Phase 1 data. Genetic recombination rates (cM/Mb), 
are shown with a light blue line. Physical positions are based on NCBI build 37 of the human 
genome. Also shown are the relative positions of genes and transcripts mapping to each region of 
association. The lower panel shows the chromatin state segmentation track (ChromHMM) in 
HCT116 CRC and GM12878 lymphoblastoid cell lines.  
 
Figure 3: Quantile-Quantile (Q-Q) plot of observed and expected colorectal cancer association 
P-values for 200 inflammatory bowel disease risk SNPs (15, 16). 
 
Figure 4: Hive Plot of common protein-protein interactions between colorectal cancer and 
inflammatory bowel disease defined by risk SNPs. Each arc represents an interaction between 
two proteins, and the distance from the centre of the plot corresponds to a greater number of 
protein-protein interactions (higher degree of the node). The left arm represents proteins that were 
only identified using the CRC SNPs, the right arm represents proteins that were only identified 
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using the IBD SNPs, and the central arm represents the common proteins, highlighting the 
previously associated tag genes. 
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TABLES 
 
Table 1: Table of the IBD SNPs with FDR corrected P-value < 0.05 in the CRC GWAS.  
 
 
rsid Chr Position Tag genes CRC risk allele IBD risk allele CRC RAF CRC p-value CRC FDR corrected CRC OR CRC 95% CI 
rs12568930 1 22,702,231 WNT4, CDC42 T T 0.85 6.58x10
-05
 3.29x10
-03
 1.12 (1.06; 1.18) 
rs7554511 1 200,877,562 GPR25, C1orf106 A C 0.29 6.95x10-04 0.02 1.08 (1.03; 1.13) 
rs7608910 2 61,204,856 PUS10, REL A G 0.63 7.28x10
-04
 0.02 1.07 (1.03; 1.12) 
rs17229285 2 199,523,122 PLCL1, SATB2 C C 0.49 2.46x10
-03
 0.04 1.06 (1.02; 1.1) 
rs2382817 2 219,151,218 TMBIM1, PNKD C A 0.62 1.02x10
-05
 1.02x10
-03
 1.09 (1.05; 1.14) 
rs4722672 7 27,231,762 HOXA13, HOXA11 C C 0.20 2.46x10
-03
 0.04 1.08 (1.03; 1.13) 
rs174537 11 61,552,680 MYRF, TMEM258 G T 0.67 2.63x10
-03
 0.04 1.06 (1.02; 1.11) 
rs653178 12 112,007,756 ATXN2, MAPKAPK5 T C 0.54 2.23x10-05 1.49x10-03 1.09 (1.05; 1.13) 
rs17085007 13 27,531,267 GPR12, UPS12 C C 0.19 5.81x10
-04
 0.02 1.09 (1.04; 1.15) 
rs941823 13 41,013,977 MRPS31, FOXO1 T C 0.27 2.47x10
-03
 0.04 1.07 (1.02; 1.12) 
rs516246 19 49,206,172 FUT2, MAMSTR T T 0.54 4.71x10
-04
 0.02 1.07 (1.03; 1.11) 
rs913678 20 48,955,424 CEBPB, PTPN1 C T 0.34 7.30x10
-06
 1.02x10
-03
 1.10 (1.05; 1.14) 
50
51
52
53
54
55
56
57
58
59
60
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ABBREVIATIONS 
 
CRC: colorectal cancer 
GWAS: genome-wide association studies 
LD: linkage disequilibrium 
IBD: inflammatory bowel disease 
MSI: microsatellite instability 
SNP: single-nucleotide polymorphism 
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Figure 1 Forest plot of the odds ratios for the association between rs992157 and CRC. Studies were 
weighted according to the inverse of the variance of the log of the OR. Horizontal lines: 95% confidence 
intervals (95% CI). Box: OR point estimate; its area is proportional to the weight of the study. Diamond: 
overall summary estimate, with confidence interval given by its width. Vertical line: null value (OR = 1.0).  
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Figure 2 Regional plot of association results and recombination rates for the 2q35 locus. In the panel, 
−log10 P values (y axis) of the SNPs are shown according to their chromosomal positions (x axis). The top 
SNP is shown as a large triangle and is labelled by its rsID. The colour intensity of each symbol reflects the 
extent of LD with the top SNP: white (r2 = 0) through to dark red (r2 = 1.0), with r2 estimated from the 
1000 Genomes Phase 1 data. Genetic recombination rates (cM/Mb), are shown with a light blue line. 
Physical positions are based on NCBI build 37 of the human genome. Also shown are the relative positions of 
genes and transcripts mapping to each region of association. The lower panel shows the chromatin state 
segmentation track (ChromHMM) in HCT116 CRC and GM12878 lymphoblastoid cell lines.  
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Figure 3 Quantile-Quantile (Q-Q) plot of observed and expected colorectal cancer association P-values for 
200 inflammatory bowel disease risk SNPs  
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Figure 4 Hive Plot of common protein-protein interactions between colorectal cancer and inflammatory bowel 
disease defined by risk SNPs. Each arc represents an interaction between two proteins, and the distance 
from the centre of the plot corresponds to a greater number of protein-protein interactions (higher degree of 
the node). The left arm represents proteins that were only identified using the CRC SNPs, the right arm 
represents proteins that were only identified  
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